Rx Cost Containment At CareFirst Driven By Physician Incentives
This article was originally published in The Pink Sheet Daily
Legal changes that allow more data sharing can encourage value-based contracting, Executive VP-Medical Affairs Blum says
You may also be interested in...
Rate of growth in prescription drug spending is expected to average 6.7% per year from 2016 through 2025, National Health Expenditures report from CMS projects.
Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing ‘behind us’ with a legislative compromise.
Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.